Prostate cancer drug now available to more patients with aggressive form of disease [FOX News]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: FOX News
A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food and Drug Administration (FDA) has expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy (RLT) that is given before chemotherapy. (RLTs are a form of targeted nuclear medicine that doctors use to treat multiple types of cancer , according to Novartis.) The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of drugs used in the treatment of metastatic prostate cancer. Pluvicto first got FDA approval on March 23, 2022, but this new expanded approval triples the number of patients eligible to receive the drug , according to a Novartis press release. The drug is administered through an IV into the
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Has Novartis' 24.5% Surge Left Further Upside After Strong Pipeline and Cash Flow Gains? [Yahoo! Finance]Yahoo! Finance
- Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report [Yahoo! Finance]Yahoo! Finance
- Novartis breaks ground on flagship manufacturing hub in North Carolina [Yahoo! Finance]Yahoo! Finance
- Novartis breaks ground on flagship manufacturing hub in North CarolinaGlobeNewswire
- Drugmaker Novartis begins work on Research Triangle expansion [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website